2877 Share Price Performance
HK$8.33
-1.58 (-15.94%)
Price HK$8.33
Share PriceHK$8.33
China Shineway Pharmaceutical Group (HKG:2877) Will Pay A Dividend Of CN¥0.12
Sep 01
China Shineway Pharmaceutical Group Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
2877 Community Narratives
There are no narratives available yet.
China Shineway Pharmaceutical Group Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 1.10
- Gross Margin
- 73.36%
- Net Profit Margin
- 24.77%
- Debt/Equity Ratio
- 4.2%
China Shineway Pharmaceutical Group Limited Competitors
Snowflake Analysis
About 2877
- Founded
- 2002
- Employees
- 2867
- CEO
- WebsiteView website
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of BH Corporate Services Ltd.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 0.5%
- 3 Months: 17.0%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market has been flat. As for the longer term, the market has risen 24% in the past 12 months. Earnings are forecast to grow by 27% annually. Market details ›